@dimerixltd

(ASX: $DXB) A #drugdiscovery and development company developing innovative new drug therapies for unmet medical needs globally #biotech #kidneydisease #covid19

dimerix.com
Joined March 2017
  • Tweets521
  • Following313
  • Followers687
311Media
🎥 Watch the recording: $DXB CEO Dr Nina Webster’s presentation at the Ignite Partners Investment Summit in Hong Kong last week is now available to view here: youtube.com/watch?v=gA26MrkP… $DXB #Investorpresentation #ASXbiotech

Presentation: Dimerix - Ignite Investment Summit, Hong Kong, October...

Dimerix is a clinical-stage biopharmaceutical company focused on br...

youtube.com
1
156
New human data presented at #KidneyWeek2026 provides independent evidence that further supports the biological rationale behind Dimerix’s lead asset, DMX-200 in FSGS. Read the full announcement here: investors.dimerix.com/invest… $DXB #FSGS #NEPTUNE
6
153
@Stockhead_AU explores why OLE studies can provide valuable long-term clinical data in drug trials. For $DXB, an encouraging 93% of eligible ACTION3 #FSGS patients have elected to continue into the OLE. Read more here:  stockhead.com.au/health/the-…

The quiet catalyst: Why open-label extension trials matter for ASX biotechs | Stockhead

Open-label extension trials provide long-term follow-up after a main trial and are an important part of drug development for ASX biotechs.

stockhead.com.au
1
142
Dimerix CEO Dr Nina Webster presented at the Ignite Partners Summit in Hong Kong this week, providing an overview of the $DXB opportunity to an audience of investors from the region. The presentation can be accessed here: investors.dimerix.com/invest… #FSGS #kidneydisease #ASXbiotech
1
5
150
Important milestone: 100 patients complete 2yr double-blind treatment period in $DXB's ACTION3 Phase 3 #trial of DMX-200 in #FSGS. 93% are continuing into OLE study, enabling collection of long-term safety and clinical data. 🔗 investors.dimerix.com/invest…
1
6
196
$DXB presented at the Canaccord Genuity (@CG_Driven) Drug & Device Conference this week, highlighting progress with DMX-200 in FSGS, 5 global licensing partnerships and the potential of DMX-652 in AKI. Full presentation here: investors.dimerix.com/invest… #ASX #FSGS #kidneydisease
2
181
A significant milestone for $DXB. The first patient has completed 4 years of continuous clinical study participation, spanning ACTION3 & OLE study. With 93% of ACTION3 participants choosing to enter the OLE, we’re grateful for the commitment of patients, families & investigators.
1
5
199
Read the full announcement here: investors.dimerix.com/invest… #ACTION3
2
45
$DXB CEO & Managing Director, Dr Nina Webster, will be presenting clinical & commercial updates for the company at the upcoming Canaccord Genuity (@CG_driven) Drug & Device Conference on 12–13 October at the Elysium Hotel, Noosa. #CGDrugandDevice #biotechinvesting
4
187
$DXB CEO Dr Nina Webster presented at today’s ASX SMIDcaps Conference, outlining our commercial & clinical growth opportunities. Thank you @ASX for hosting & supporting SMID caps companies in Australia. Access our presentation: investors.dimerix.com/invest… #FSGS #SMIDcaps #ASXBiotech
6
255
Dr Nina Webster, MD and CEO of $DXB recently joined Wei Sim at @Homodeus Research to discuss Dimerix's recent achievements, key value drivers and upcoming catalysts. đź”— Watch the webinar: youtu.be/EU6Vu96KOik #FSGS #KidneyDisease #ClinicalTrials
2
185
A new @StockheadAU article explores how ASX healthcare companies are using licensing partnerships to support drug development, featuring Dimerix and its 5 global partnerships supporting lead asset DMX-200. Read more: stockhead.com.au/health/asx-… $DXB #ASX #Biotech #DMX200

ASX healthcare stocks look to partner up to fund drug development | Stockhead

ASX healthcare stocks are turning to licensing and partnering deals to fund drug development, with Dimerix and Neuren showing the potential rewards.

stockhead.com.au
7
230
Not long to go: $DXB will present at the @ASX SMIDcaps Conference, next Wed 23 Sept at the State Library of NSW. Join in person or online where CEO Dr Nina Webster will share our business strategy & latest milestones. Register: shorturl.at/pTrsb #ASXSMIDcaps #Biotech
3
207
Join Dimerix & @sharewiseau next Monday, 21 Sept at 2pm. Dr Nina Webster will discuss our Phase 3 ACTION3 trial, expanding renal pipeline with DMX-652, & global commercial partnerships. Register: shorturl.at/512jM #Biotech #ASX $DXB
1
131
$DXB will present at today’s E&P Small Cap Healthcare Conference in Sydney. You can access a copy of the presentation here:  investors.dimerix.com/invest… #raredisease #kidneydisease #smallcap #biotechinnovation
1
4
231
$DXB granted a key composition of matter #patent for DMX-652 in Mexico - the 2nd largest pharma market in Latin America and 12th largest globally. Patent strengthens our commercialisation plan & growing patent portfolio. More here: investors.dimerix.com/invest…
1
7
302
We’re pleased to share @EurozHartleys Limited’s latest research highlighting an updated price target following our recent announcement that Dimerix ($DXB) has secured access to a A$34m non-dilutive funding facility. Full note here: investors.dimerix.com/invest… #analystresearch
1
7
848
Dimerix has released an updated investor presentation, covering our DMX-200 Phase 3 & DMX-652 Phase 2 trials in rare #kidneydisease, and corporate strategy. View here: investors.dimerix.com/invest… $DXB #investorpresentation #ASXbiotech
1
5
276
Thank you to the @Stockhead_AU team for sharing our latest clinical updates. In this video, @tylahtully discusses our recent funding announcement, and provides updates on our Phase 3 and Phase 2 #kidney disease trials. $DXB #FSGS 🔗 shorturl.at/5Tz47
3
179
We were honoured to be named a winner at the Governor of Victoria Export Awards. CEO Dr Nina Webster received the Global Victoria Women’s Award, recognising women whose leadership is shaping Victoria’s success. More here: global.vic.gov.au/our-progra… #GlobalVictoria #ExportAwards $DXB
1
8
332
Load more